Drug intelligence / Profile preview

MS201408-0005B

Development stage: Unknown
Lead developer: Merck
Administration: Oral

Overview

MS201408-0005B is an experimental agent investigated in combination studies with M4112 (an IDO1/TDO2 inhibitor) and other compounds. It has been used in phase I clinical trials designed to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity in patients with advanced or metastatic solid tumors. The mechanism of action, precise modality, chemical structure, and independent therapeutic relevance of MS201408-0005B have not been disclosed in public sources, but it is known as a study drug used in combination arms of early oncology trials by EMD Serono/Merck KGaA.[1][3][5][7]

Beyond the preview

Go deeper on MS201408-0005B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MS201408-0005B.

Explore the full profile